Legal Battle Erupts: Novo Nordisk Challenges Eli Lilly’s GLP-1 Advertising
The pharmaceutical industry is witnessing a high-stakes legal confrontation between two of its most prominent players, Novo Nordisk and Eli Lilly. The dispute, filed in the U.S. District Court for the District of New Jersey, centers on aggressive advertising strategies surrounding blockbuster GLP-1 receptor agonist medications, which have revolutionized treatment for obesity and type 2 … Read more



